Personalized cancer vaccine plus Keytruda for lung cancer after surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your non-small cell lung cancer, and the cancer was stage II, IIIA, or IIIB (N2).
- You have no signs of cancer left after surgery (no evidence of disease).
- You have already received at least one round of platinum-based chemo after your surgery.
- You have not had any prior immunotherapy (like Keytruda) or radiation for this lung cancer.
- You do not have an active autoimmune disease that needed treatment in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a personalized combination of radiation and immunotherapy for people with locally advanced non-small cell lung cancer that has a high level of a protein called PD-L1. It aims to improve treatment by tailoring the therapy to each patient's tumor.
This trial tests a combination of SYS6010 and an immunotherapy drug (anti-PD-(L)-1) given after surgery to prevent non-small cell lung cancer from coming back. It's for people whose cancer was removed but didn't shrink much with prior treatment before surgery.
This trial tests two medicines given before lung cancer surgery: benmelstobart (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted therapy that stops blood vessel growth to tumors). The goal is to see if they make the cancer disappear completely by the time of surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.